Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders

Drugs
J E Frampton, D Faulds

Abstract

Parnaparin is a low molecular weight (LMW) heparin which, like other members of its class, apparently demonstrates a greater antithrombotic effect relative to its anticoagulant activity when compared with the unfractionated heparin (heparin) from which it is derived. Moreover, subcutaneous parnaparin has a greater bioavailability and longer half-life than heparin, permitting once-daily administration for the prophylaxis of deep venous thrombosis (DVT) or the treatment of established vascular disorders. Prophylaxis with a 7-day regimen of parnaparin 3200 or 6400 IUaXa/day has consistently been associated with a lower incidence of confirmed DVT compared with usual prophylactic regimens of heparin. This intertreatment difference reached statistical significance in a large multicentre study involving a total of 610 surgical patients (3.2% for parnaparin vs 6.3% for heparin). Thus far, however, comparisons of parnaparin with other LMW heparins for this indication are unavailable. Parnaparin has demonstrated equivalent efficacy to heparin in the treatment of established vascular disorders, including phlebopathies and related syndromes, as well as peripheral arterial occlusive disease. Parnaparin also showed some benefit as an adjunct...Continue Reading

Citations

Nov 16, 2007·Obesity Surgery·Pietro ForestieriPatrizio Ferrari
Jul 20, 2007·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Milena MontebugnoliPatrizio Ferrari
Dec 10, 2003·Expert Opinion on Emerging Drugs·Prabal K Chatterjee, Christoph Thiemermann
Feb 17, 2017·International Journal of Experimental Pathology·Francesca BonominiRita Rezzani
Apr 14, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Min QiuJunzhi Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.